RE:RE:Inflation Reduction Act (IRA) boosts biological drugs “Biologics represent a more durable revenue potential based on a number of factors, including differentiated access and affordability to the patient, IRA considerations and patent expiration timeline,” according to Suneet Varma, commercial president of Pfizer Oncology.
Pfizer’s messaging to investors is that the company is shifting toward a “more balanced portfolio mix,” Varma said, which will be driven by the increased leveraging of currently commercialized ADCs, the launch of new indications for current bispecific antibodies and the development of next-generation biologics.